Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Boehringer Ingelheim
Express Scripts
Colorcon
Johnson and Johnson

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

JORNAY PM Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Jornay Pm patents expire, and what generic alternatives are available?

Jornay Pm is a drug marketed by Ironshore Pharms and is included in one NDA. There are ten patents protecting this drug.

This drug has twenty-seven patent family members in fourteen countries.

The generic ingredient in JORNAY PM is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Jornay Pm

A generic version of JORNAY PM was launched as methylphenidate hydrochloride by ACTAVIS LABS FL INC on December 14th, 2019.

Summary for JORNAY PM
Drug patent expirations by year for JORNAY PM
Drug Prices for JORNAY PM

See drug prices for JORNAY PM

Pharmacology for JORNAY PM

US Patents and Regulatory Information for JORNAY PM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-004 Aug 8, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-003 Aug 8, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-005 Aug 8, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-005 Aug 8, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Ironshore Pharms JORNAY PM methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 209311-005 Aug 8, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Boehringer Ingelheim
Harvard Business School
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.